Tag: tumor necrosis factor (TNF)

1. In this randomized, double-blind, phase two trial, the use of golimumab led to more C-peptide production, indicative of improved endogenous function, compared to placebo in new type 1 diabetics. 2. Patients that received golimumab used less exogenous insulin compared to placebo. Evidence Rating Level: 2 (Good) Study Rundown: TNF-α has been...
1. Tumor necrosis factor inhibitor exposure in patients with autoimmune disease, particularly rheumatoid arthritis, was associated with increased risk of inflammatory central nervous system events. Evidence Rating Level: 2 (Good) The U.S. Food and Drug Administration has approved five tumor necrosis factor (TNF) inhibitors as immunotherapies for autoimmune diseases: etanercept, adalimumab, infliximab,...
1. Tumor necrosis factor inhibitor exposure in patients with autoimmune disease, particularly rheumatoid arthritis, was associated with increased risk of inflammatory central nervous system events. Evidence Rating Level: 2 (Good) The U.S. Food and Drug Administration has approved five tumor necrosis factor (TNF) inhibitors as immunotherapies for autoimmune diseases: etanercept, adalimumab, infliximab,...